Wednesday, December 22, 2010

MicroBits: Signs of Life for Biotech IPOs, Dim View of VCs, and FDA Slows Med-Tech Innovation...

After a near absence of IPOs for two years, the biotech industry is dipping its toe into the public markets again. So far this year, 12 biotech companies have launched IPOs. In comparison only three IPOs were filed by biotech companies in 2009 and just one in 2008. One industry watcher called this year's dozen "a miracle" and predicted the number of biotech companies going public next year could hit 25.
A Dim View of Betting on Start-Ups
Sean Parker, the entrepreneur behind Napster and Facebook now turned investor, talks about the state of the venture capital industry. He's come to a depressing conclusion about the money industry that he says used to be �the engine of innovation� for this country. �The risk-reward doesn't work out in favor of putting money into venture capital anymore,� he said, even though he himself is a partner in a VC firm that owns stakes in Facebook and SpaceX.
FDA Slows Medical Technology Innovation
If you throw in enough small pebbles in the stream, you can dam it up. Similarly, add enough rules, regulations, and requirements, and suddenly innovation begins to look a lot less attractive. A new study entitled �FDA Impact on U.S. Medical Technology Innovation: A Survey of Over 200 Medical Technology Companies� makes this point very well. The blogger's bottom line: If Washington is genuinely serious about jobs and economic growth, it's time to encourage innovation, not discourage it.
Subscribe to Functional Inspiration:
MicroCap Investor delves deep into the world of small stocks to identify big winners. Levine targets innovative companies on the path of the new and revolutionary, developing technologies that disrupt entrenched markets to create tremendous value.
About Josh Levine and Levine's MicroCap Investor
Josh Levine has 25 years of senior-level experience in analyzing technology trends and investing in top-performing micro- and small-cap stocks. He excels at assessing management teams and evaluating new innovations and their impact on corporate valuations.
In 2002 he joined independent investment-research boutique ChangeWave Research, where he was editor of ChangeWave MicroCap Investor since 2004, becoming Levine's MicroCap Investor in 2010. He has been editor of the flagship ChangeWave Investing since 2007.
Levine is also senior analyst for ChangeWave Research. Through its survey network comprised of 25,000 members, ChangeWave tracks the rate of change in corporate and consumer demand trends and provides the results through an institutional research subscription service. Its macroeconomic research is among the best on Wall Street.
More on Levine's bio:
Learn more about subscribing to Levine's MicroCap Investor: is partnered with Josh Levine and MicroCap Investor as part of its mission to provide investors with research tools to explore the world of small stocks. The team operates this web site and manages the administration and marketing for MicroCap Investor. is a leading investment and industry research portal, with resources covering high-growth sectors including technology, biotech and cleantech.
Levine's MicroCap Investor
Contact us

No comments: